Peptides in Development for Alzheimer’s Disease
|Product Name||Active Ingredient||Company Name||Highest Phase of Development||Mode of Action|
|CAD106||amyloid beta peptide||Cytos Biotechnology AG, Novartis AG, Amgen Inc||Phase III||Alzheimer's Disease Vaccine, Immunostimulant, Therapeutic Vaccine|
|ACI-24||--||AC Immune SA||Phase II||Alzheimer's Disease Vaccine, Anti-Alzheimer's Agent, Antiplaque Agent, Immunostimulant, Therapeutic Vaccine|
|AL208||davunetide||Allon Therapeutics Inc||Phase II (current status unknown)||Anti-Alzheimer's Agent, Neuroprotectant, Nootropic (Cognitive Enhancer)|
|UB311||--||United Biomedical Inc, United Neuroscience Inc||Phase II||Alzheimer's Disease Vaccine, Immunostimulant, Therapeutic Vaccine|
|AADvac1||--||Axon Neuroscience SE||Phase I||Alzheimer's Disease Vaccine, Immunostimulant, Therapeutic Vaccine|
|ABVac40||amyloid beta 40 peptide||Araclon Biotech SL, Grifols International SA||Phase I||Alzheimer's Disease Vaccine, Immunostimulant, Therapeutic Vaccine|
|ABVac42||amyloid beta 42 peptide||Araclon Biotech SL, Grifols International SA||Phase I||Alzheimer's Disease Vaccine, Immunostimulant, Therapeutic Vaccine|
|ACC002||amyloid beta peptide||Pfizer Inc, Wyeth||Phase I (current status unknown)||Alzheimer's Disease Vaccine, Therapeutic Vaccine|
|ACI-35||--||AC Immune SA, Janssen Pharmaceuticals Inc||Phase I||Alzheimer's Disease Vaccine, Immunostimulant, Therapeutic Vaccine|
|GM605||--||Genervon Biopharmaceuticals LLC||Phase I||Anti-Alzheimer's Agent, Antioxidant, Neuroprotectant, Neuroregenerant|
|RAP105||--||RAPID Pharmaceuticals AG||Phase I||Anti-Alzheimer's Agent, Neuroprotectant, Nootropic (Cognitive Enhancer)|
|V950||--||Merck & Co Inc||Phase I||Alzheimer's Disease Vaccine, Immunostimulant, Therapeutic Vaccine|
Bachem offers H-7442 and H-7438 which are Beta Amyloid (1-42) and (1-40) peptides treated with HFIP.
Till date it has only been possible to detect AD in late stage when there has already been significant damage to the brain. Aβ can be detected in cerebrospinal fluid through a lumbar region puncture and PET (Positron emission tomography) scans. Both methods are expensive and not readily available everywhere.
Aβ build-up in the eyes of patients in early years has become a biomarker for this disease. The peptide build-up begins 15-20 years before the Alzheimer’s symptoms appear. Studies were conducted and concluded to find significant correlation of the levels of Aβ build-up in eyes and the Aβ build-up in the brain. An abstract prepared by the scientists for AAIC 2014 gives the results for 40 participants out of 200 totals in the study.
Bachem offers more than 190 Alzheimer’s disease related research products available online.
- β-Amyloid (1-43), (1-42), (1-40) and Fragments (46 peptides)
- Modified Amyloids (18 peptides)
- Modifiers of Aß-Aggregation (9 peptides)
- β-Amyloid (HFIP-treated) and Salts (HCI,TFA) (5 peptides)
- FRET β-Amyloid Substrates (15 peptides)
- Labeled Amyloid Peptides (Biotin, FITC, FAM, TAMRA) (12 peptides)
- Secretase Inhibitors (β- and γ) (11 peptides)
- β-Amyloid Mutations (19 peptides)
- β-Amyloid (APP) Precursor 770 Fragments (10 peptides)
- Related Products (59 peptides)
- AB Antagonist
- Amyloid-like Proteins
- Amyloid Bri Peptides
- Amyloid Dan Peptides
- Amyloid P-Component
- Humanins and Colivelin
- Various Related
- Recombinant Source
What is your official job title at Bachem?
Group Leader Business Intelligence.
How long have you been with Bachem? Where did you work before Bachem?
I am with Bachem for 2 years. Prior to my Bachem time, I was working at Solvias, Switzerland as a Key Account Manager.
Briefly, what do you do at Bachem?
Management of information for industry trends in the synthetic peptides market, and deriving activities from this information.
What is your academic background?
I’m a Ph.D. chemist by education.
What do you like to do outside of work?
I enjoy spending my leisure time in swimming, hiking, travelling and listening to music.
What do you like most about your job?
The job is very multi-disciplinary, e.g. covering scientific questions, IT-related, attending trade shows and conferences.
Thank you very much Michael.